Victory Capital Management Inc. Has $29.14 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Victory Capital Management Inc. decreased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 255,040 shares of the company's stock after selling 52,476 shares during the quarter. Victory Capital Management Inc. owned 0.23% of Vaxcyte worth $29,143,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in shares of Vaxcyte in the first quarter valued at $298,000. Russell Investments Group Ltd. acquired a new position in shares of Vaxcyte in the 1st quarter valued at $1,288,000. Vanguard Group Inc. lifted its holdings in shares of Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company's stock worth $665,152,000 after acquiring an additional 1,284,883 shares during the period. Covestor Ltd boosted its position in shares of Vaxcyte by 451.7% during the 1st quarter. Covestor Ltd now owns 1,153 shares of the company's stock valued at $79,000 after acquiring an additional 944 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its stake in Vaxcyte by 11.1% in the first quarter. Ameritas Investment Partners Inc. now owns 10,545 shares of the company's stock valued at $720,000 after acquiring an additional 1,050 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PCVX shares. Jefferies Financial Group lifted their price objective on Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, November 6th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Mizuho lifted their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a report on Tuesday, September 10th. Finally, Bank of America upped their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of "Buy" and an average price target of $147.50.

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. The trade was a 8.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the sale, the chief executive officer now directly owns 478,888 shares of the company's stock, valued at $37,822,574.24. This represents a 3.04 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 117,464 shares of company stock valued at $12,640,276. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Stock Down 0.4 %

NASDAQ:PCVX traded down $0.34 during mid-day trading on Monday, reaching $86.49. 2,007,911 shares of the company were exchanged, compared to its average volume of 891,006. The stock has a market cap of $10.78 billion, a PE ratio of -18.80 and a beta of 1.01. Vaxcyte, Inc. has a 12 month low of $48.24 and a 12 month high of $121.06. The company has a fifty day moving average of $110.09 and a 200 day moving average of $88.98.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.27. During the same period last year, the company posted ($0.91) earnings per share. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.